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The three Tropomyosin Receptor Kinases, Trk-A, Trk-B, and Trk-C, belong to the 
second largest class of membrane proteins, the Receptor Tyrosine Kinases (RTKs).  The Trks are 
important for the survival and the function of neurons in the central nervous system, and have 
been implicated in many cancers. Currently, the Trks are known to bind neurotrophins and get 
activated upon lateral dimerization, but there is no quantitative or mechanistic understanding of 
the dimerization process.  This is one bottleneck in the development of Trk targeted therapies. 
The goal of this project is to characterize the interactions that control Trk activation in the 
plasma membrane using a FRET-based method. 
To determine the propensity for Trk dimerization in quantitative terms, I have 
characterized the dimerization of each Trk receptor over a broad range of concentrations in live 
cells. This has been done in the absence and in the presence of their ligands, the neurotrophins. I 
have found that the Trk receptors form dimers even in the absence of ligands, stabilized mainly 
via contacts in the transmembrane/intracellular domains, and binding of their cognate ligands 
stabilizes the dimers and induces changes in the conformations of the kinase dimers.   
I have also explored the mechanism of ligand functional selectivity for Trk-A and Trk-B.  
Ligand functional selectivity, or ligand biased signaling, is a phenomenon in which different 
ligands lead to different biological outcomes while interacting with the same receptor.  I have 
shown that different ligand-bound Trk-A dimers have different stabilities, and that different 
ligand-bound Trk-B dimers exhibit both different stabilities and different intracellular 




In the long run, this new basic knowledge about Trk interactions in the absence and 
presence of ligands may be used for the design of targeted Trk inhibitors, for the benefit of 
human health.  
Readers 
Professor Kalina Hristova (Advisor) 
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Chapter 1: Introduction 
1-1: Membrane Proteins 
The sequenced human genome has shown that membrane proteins account for 30% of all 
the proteins. However, only 2% of these protein structures are deposited in the protein data bank, 
and thus very few high-resolution structures are available [1]. This is due to inherent limitations 
that the researchers face when working with membrane proteins in order to crystalize them 
[2][3]. There is a strong need to overcome these challenges or to discover alternative study 
methodologies since membrane proteins represent 60% of drug targets being explored for 
various therapies, due to their crucial role in initiating signaling pathways [4][5]. 
1-2: Protein-Protein Interactions 
 
The membrane proteins are embedded in the cell’s plasma membrane, where they control 
incoming messages to the cells by various mechanisms. One mechanism by which these proteins 
control signaling is via protein-protein interaction in the membrane. Protein-protein interactions 
in plasma membranes play important role in regulating the transmission of signals from the 
external environment to the cell cytoplasm. These proteins initiate signaling through various 
downstream pathways and control biological responses such as cell growth, survival, 
differentiation, and migration, and thus are under study for targeted drug discovery [6][7][8][9] 
[10][11]. 
1-3: Receptor Tyrosine Kinases (RTKs) 
 
Receptor Tyrosine Kinases (RTKs) are one class of membrane proteins and of interest to 
scientific research due to their diversity in activation and their significant role in diseases like 
cancers, diabetes, inflammatory disorders, and bone disorders.  These disorders occur due to 
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dysregulation caused by genetic alterations or other factors and lead to abnormal signaling [8], 
[11]. New drugs are being developed to either block or alter RTKs activity in diseases. In terms 
of their structure, these membrane receptors contain an extracellular (EC) domain, where ligand 
binds, a transmembrane domain (TM), which goes through the plasma membrane, and a tyrosine 
kinase domain (TK), which is present in the intracellular region; they also contain carboxy 
terminal and juxtamembrane regions [8] . RTKs share similarities in their structure, but the 
responses elicited by each RTK can be very different as they regulate highly specific pathways 
involved in distinctive cellular responses. Thus far, 58 RTKs have been identified belonging to 
20 subfamilies in humans, based on the molecular characteristics of their extracellular domains 
[12]. 
For RTK activation, in general, the binding of ligand to the receptor initiates downstream 
signaling [11][13][14]. Currently, there are two competing models proposed for RTK interaction 
and activation in the plasma membrane as shown in Figure 1-1. Figure 1-1-A is a representation 
of the canonical model or “diffusion-based” model, where two monomers present in the plasma 
membrane come in close proximity in the presence of ligand. As a result, dimerization occurs. 
The tyrosine kinase domains get activated, and initiate biological signaling by recruiting 
downstream molecules (adaptors) to the phosphorylated sites of the receptors.   The adaptors are 
phosphorylated by the RTKs and initiate biological responses [15][16]. Figure 1-1-B is a 
representation of a model known as the “pre-formed dimer model”. In this model, pre-formed 
dimers exist in the absence of ligands. Upon ligand binding these dimers are stabilized. 
Furthermore, there is a change in the conformation of the dimers, leading to the activation of the 
kinase domains to initiate downstream signaling as mentioned above [17][18]. The unliganded 
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dimers have been shown to have basal level phosphorylation activity and are associated with the 
progression of various disorders and cancers [8][19][20].  
These two models for RTK interaction and activation differ due to the absence or 
presence of unliganded RTK dimers. In this thesis, I investigate which of the RTK activation 
model is applicable to one subfamily of RTK receptors, the Tropomyosin receptor kinases 
(Trks). 
1-4: Tropomyosin Receptor Kinases (Trks) 
The subfamily of Tropomyosin receptor kinases (Trks) consists of three members: 
Tropomyosin receptor kinase-A, B, and C. The Trks extracellular domains consist of leucine rich 
repeats (LRR) flanked by two cysteine clusters, followed by two immunoglobulin like domains 
(Ig1 and Ig2) as shown in figure 1-2 [21]. The three Trk receptors are highly similar in terms of 
their structure. The protein sequence percent homology for Trk-A and Trk-B is 49%, for Trk-A 
and Trk-C it is 51%, and for Trk-B and Trk-C it is 55%. The kinase domain sequence percent 
homology for all three Trks are 71% [22][23]. Despite very similar structures, these Trks play 
distinct roles in the development of the central nervous system. Trk-A is important for the 
development of normal sympathetic neurons, Trk-B is responsible for proper development of 
sensory neurons, and Trk-C has overlapping role with Trk-A during sympathetic neuron 
development. Trk-C is present during early stages of development while Trk-A predominates 
during later stages of the development of sympathetic neurons [24][25][26][27][28][29].  
The Trk receptors are activated by four ligands, called neurotrophins: Nerve Growth 
Factor  (NGF), Neurotrophin -3 (NT-3), Neurotrophin-4 (NT-4) and brain-derived neurotrophic 
factor (BDNF) [30], [31], [32], [33]. The Trks play diverse roles in the development of the 
mammalian nervous system by promoting survival and differentiation of neurons in the presence 
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of neurotrophins [34]. They control synaptic strength, plasticity, neuronal survival, proliferation, 
migration, axonal growth/guidance and patterning, injury protection, and neuronal apoptosis 
[32][33][35][36][37][38][30][39]. Trks have been shown to be involved in pain sensation 
malignancy and in tumor growth and survival [22][40]. Trk-A has been associated with papillary 
thyroid, colon cancer, neuroblastoma, and lung cancers [22][41][42][43], and also with 
congenital insensitivity to pain with anhidrosis (CIPA)[44][45]. Trk-B has been reported to be 
involved in metastatic stages and in aggressive tumor growth in  human pancreatic cancer and 
neuroblastoma [46], [47]. Trk-C has been involved in secretory breast carcinoma and in acute 
myeloid leukemias (AML)[48]. 
 There are multiple mechanisms responsible for the involvement of Trks in diseases and 
cancers. CIPA has been associated with point mutations in Trks. Chimeric oncogenes which are 
created by chromosomal rearrangement are involved in the transformation, proliferation, and 
survival of cancer cells. In these chimeric exchanges, the extracellular domain belongs to 
different genes while the TM and TK domains are from a Trk receptor [49]. Gene deletions and 
splice variations leading to loss of the extracellular region have also been shown to be associated 
with AML and neuroblastomas [21].This linkage of the Trk family to cancers and CIPA has 
promoted a significant interest in the development of targeted therapies for Trk associated 
malignancies. However, development of successful Trk inhibitors is still a challenge. One of the 
main reasons for the current low success rate for Trk targeted therapies is the incomplete 
understanding of Trks activation and interactions in the plasma membrane. This lack of basic 






1-5: Ligand Biased Signaling for Trk-A and Trk-B 
 
Tropomyosin receptor kinase-A and B are also involved in ligand-biased signaling, in 
which one receptor responds to multiple ligands to initiate ligand-specific downstream biological 
responses. Trk-A not only interacts with its cognate ligand hß-NGF but it also interacts with h-
NT-3, which is a cognate ligand for Trk-C. When Trk-A interacts with hß-NGF, Trk-A 
activation initiates signaling cascades which promote survival of neurons. In the presence of h-
NT-3, Trk-A activates a pathway which is involved in axon extension of neurons [50]. 
Therefore, hß-NGF and h-NT-3 differentially regulate the same Trk-A receptor, leading to 
selective biological responses. Trk-B interacts with h-NT-3 and h-NT-4, besides its cognate 
ligand h-BDNF. In the presence of h-BDNF, Trk-B generates responses which promote synaptic 
transmission and plasticity [51][52][53]. In the presence of h-NT-4, Trk-B supports the survival 
of neurons and synaptic maturation [54][54][55][56]. In the presence of h-NT-3, Trk-B mainly 
initiates signaling to promote the survival of Trk-B expressing neurons 
[57][51][52][58][59][60][61]. 
There are two existing hypotheses about this phenomenon in which different ligands 
generate different responses via the same receptor. One hypothesis is that each ligand induces 
different structural changes in the extracellular domain of the receptor, and then these changes 
are transmitted to the kinase domains via the transmembrane region, causing the kinase dimer 
configuration to change.  This leads to site-specific phosphorylation and recruitment of different 
downstream signaling molecules [62]. The second hypothesis focuses on changes in dimer 
stability in the presence of different ligands [63]. There are no studies which have investigated 
these two hypotheses for the Trk receptors, and the interactions and activation of Trk-A and Trk-
B with different ligands have not been compared. My work will explore these hypotheses in 
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terms of Trk receptor ligand-biased signaling. Receptor interactions in the plasma membrane will 
be investigated using a Förster Resonance Energy Transfer (FRET)-based method.  The 
methodology utilizes fluorophores attached to a receptor to directly quantify the interactions as 





Figure 1- 1: Representation of the canonical or “diffusion-based” and the “pre-formed dimer” 
models of RTK activation. 
A) Representation of the canonical model for RTK activation. This model assumes that RTKs 
exist as monomers in the plasma membrane in the absence of ligands. Upon ligand binding, these 
monomers dimerize and cross-phosphorylate their kinase domains to activate them. B) 
Representation of a new emerging model for RTK activation known as the pre-formed dimer 
model. In this model, RTKs exist as monomers and dimers in the absence of ligands. Upon 
ligand binding these preformed dimers undergo structural and stability changes to start 





Figure 1- 2: Structural details of the Trk-A, B, and C receptors. The extracellular regions consist 
of leucine rich repeats, which are flanked by cysteine clusters, and two immunoglobulin domains 
(Ig-1 and Ig-2). A single pass transmembrane region spans the plasma membranes and is 
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Chapter 2: Experimental Materials and Methods 
The experimental methods utilized in all the chapters are similar. The details about the 
materials utilized, the molecular cloning techniques used to generate recombinant Trk receptors, 
the cell culture and transfection protocols, the crosslinking protocol, the FRET image acquisition 
equipment, and the FRET image analysis are described in detail in this chapter.  
2-1: Trk-A, Trk-B and Trk-C Plasmids Cloning 
The pCMV5 Trk-A plasmid [1] was purchased from Addgene (# 15002). The Trk-A gene 
was amplified and cloned using the restriction enzyme method into a pcDNA3.1+ vector that has 
been previously engineered to incorporate a gene encoding for a 15 amino acid flexible (GGS)5 
linker followed by either eYFP or mTurquoise (a FRET pair)[2]. The ECTM-Trk-A plasmids, 
encoding for the Trk-A extracellular (EC) and transmembrane (TM) domains, a (GGS)5 linker, 
and either eYFP or mTurquoise, were similarly generated. The TM-Trk-A plasmids, containing 
the transmembrane (TM) domains, a (GGS)5 linker, and either eYFP or mTurquoise, were 
produced via Gibson assembly using the NEBuilder HiFi DNA assembly kit (New England 
Biolabs, E5520S), following the manufacturer’s protocols. 
The pDNR-Dual Trk-B plasmid (# HsCD00022371) and pDNR-Dual Trk-C plasmid (# 
HsCD00022362) were purchased from the DNASU Plasmid Repository. Trk-B and Trk-C, and 
their ECTM and TM versions were cloned into the pcDNA 3.1+ vector, which incorporated the 
(GGS)5 linker and the fluorescent protein (either eYFP or mTurquoiuse). Cloning was performed 
via Gibson assembly using the NEBuilder HiFi DNA assembly kit (New England Biolabs, 
E5520S). All plasmid constructs are shown in Figure 2-1. The primer design for all the constructs 







Figure 2- 1: Schematics of Trk-A, B, and C constructs, cloned for the FRET experiments. The 









Table 2- 1: Primers used to clone Trk-A, B, and C and their truncated versions. FW: forward 
primer; RV: reverse primer; SP: signal peptide; TM: transmembrane domain, ECTM: 







Figure 2- 2: The schematics of full length Trk receptor, Extracellular Transmembrane Trk 
receptor (ECTM-Trk), and Transmembrane Trk receptor (TM-Trk) attached to the fluorophores 


















2-2: Cell Culture and Transfection 
Human embryonic kidney cells (HEK293T) used in this work were a kind gift from Dr. D. 
Wirtz, Johns Hopkins University. The cells were cultured in Dublecco’s Modified Eagle Medium 
(DMEM, ThermoFisher Scientific, 31600034) with 10% fetal bovine serum (FBS, Hylone, 
SH30070.03), at 370C in the presence of 5% CO2.  
To perform the FRET experiments, HEK293T cells were seeded (2.5 X 105 cells/dish) on 
collagen coated, glass bottom petri dishes (MatTek, P35GCOL-1.5-14-C). Upon reaching 60% 
confluency, cells were transfected with 2ug of DNA using Fugene HD (Promega, E2311) 
according to the manufacturer’s protocol. In the FRET experiments, cells were co-transfected with 
different ratios of Trk-mTurquoise and Trk-eYFP DNA. Control single transfection experiments 
were also conducted, where cells were singly transfected with either Trk-mTurquoise or Trk-eYFP 
DNA; the acquired spectra were used for calibration as previously described [3]. Twenty four 
hours post transfection, cells were rinsed twice with phenol-red and serum free medium, and 
starved in the same media for 12 hours. In some experiments, the ligands human ß-nerve growth 
factor (hß-NGF, Cell Signaling Technology, 5221SC), human brain-derived neurotrophic factor 
(h-BDNF, Cell Signaling Technology, 3897S), or human neurotrophin-3 (h-NT-3, Cell Signaling 
Technology, 5237SC) were added at a concentration of 5ug/mL before imaging.   
2-3: Crosslinking  
HEK293T cells were transfected with 2ug of Trk-eYFP DNA. A membrane impermeable 
crosslinker, BS3   (bis(sulfosuccinimidyl) suberate; ThermoFisher Scientific, 21580), was used in 
the crosslinking experiments. Twenty four hours after transfection with Trk-A-YFP DNA, cells 
were incubated with 2 mM BS3 for 1 hour at room temperature. The reaction was quenched with 
20 mM Tris-HCl for 15 min. The cells were rinsed with ice-cold 1X PBS before lysing. In some 
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cases, cells were incubated with the neurotrophin hß-NGF (5ug/mL) for 10–15 min before adding 
the crosslinker. The lysates were subjected to SDS-PAGE, and the proteins were transferred to a 
nitrocellulose membrane. Trk-A-eYFP was probed using anti-GFP antibody (Cell Signaling 
Technologies, 2555S) as the primary antibody, followed by anti-rabbit HRP conjugated antibody 
(Promega, W4011). The membrane was incubated with Amersham ECL Plus TM (GE HealthCare 
Life Sciences, RPN2106) for 2 min and exposed to detect the chemiluminescent signal in a 
Chemidoc imaging system (Bio-Rad).  
2-4: Swollen Cells as Model System 
Following published protocols [3][4][5], experiments were performed in HEK293T cells 
under reversible osmotic stress as shown in figure 2-3. The reversible osmotic swelling was 
necessary because the cell membrane of live cells is highly “wrinkled,” while the reversible 
osmotic stress eliminates these ruffles [6]. Thus, the effective 3D protein concentration, 
determined using purified fluorescent protein standards of known concentration, can be converted 
into 2D receptor concentrations in the plasma membrane as previously described [3]. Before 
imaging, the serum-free media was replaced with hypotonic swelling media (1:9 serum-free media: 
diH2O, 25mM HEPES) to induce reversible osmotic stress. Typically, imaging sessions started 10 
min after the addition of the swelling buffer, and lasted about 2 hours. In some cases, neurotrophins 




Figure 2- 3: HEK293T cells under reversible osmotic stress. Top: Non-swollen cell imaged in 









2-5: Image Acquisition by Two Photon Microscopy 
A two photon microscope was used to acquire images of the swollen HEK293T cells. This 
system is equipped with a Mai Tai laser (Spectra-Physics, Santa Clara), used to generate 
femtosecond mode locked pulses and excite the fluorophores, and the OptiMis detection unit 
(Aurora Spectral Technology) which yields full fluorescence spectra for every pixel in the image. 
This microscope offers pixel level spectral resolution and line-scanning excitation capabilities [7]. 
Two images were acquired for each cell: one upon excitation at 800 nm to primarily excite the 
mTurq (donor), and a second one at 960 nm to primarily excite the eYFP (acceptor)[7]. The FSI-
FRET method was used to measure the FRET efficiency, the donor (Trk-mTurq) concentration, 
and the acceptor (Trk-eYFP) concentration in small membrane areas of a cell as shown in Figure 
2-4. More than 500 cells were analyzed in each case. To convert pixel level intensities of the 
images into concentrations, calibration solutions of purified fluorescent proteins were used as 
previously described [3]. Soluble eYFP and mTurquoise were produced following a previously 


































Figure 2- 4: The fully quantified spectral Imaging (FSI) method was used to unmix pixel-level 
FRET spectra. A: Cells expressing Trk-mTurq are used to obtain the mTurq spectra. B: Cell 
expressing Trk-eYFP are used to obtain the eYFP spectra. C: In cells expressing both Trk-mTurq 
and Trk-eYFP, regions were selected and the FSI method was used to decompose the FRET 
spectra into donor and acceptor contributions. This allows us to determine the FRET efficiencies, 





2-6: Image Analysis 
Analysis of the acquired images is done using the Fully Quantified Spectral Imaging 
(FSI) method [3]. We use images of calibration solutions containing pure soluble donors and 
acceptors at known micromolar concentrations to calculate donor and acceptor concentrations in 
the membrane. We fit the raw FRET data while varying two parameters: the intrinsic FRET (Ẽ), 
which is a structural parameter, and the equilibrium association constant (K) to generate 
dimerization curves.  
The measured FRET efficiency has contributions due to both (i) specific dimerization of 
the Trk receptors, ED and (ii) stochastic or “proximity FRET” that arises due to the random 
proximity of donors and acceptors in the two dimensional membrane, Eprox [9][10]. FRET 
measurements are corrected for the random, non-specific close proximity of the donors and 
acceptors using computer simulated FRET [11]. Thus, the measured (apparent) FRET efficiency 
Eapp in the experiment is described by the following equation: 
𝐸𝑎𝑝𝑝  =  
 𝐸𝑝𝑟𝑜𝑥+ 𝐸𝐷−2 𝐸𝑝𝑟𝑜𝑥𝐸𝐷
1 − 𝐸𝐷𝐸𝑝𝑟𝑜𝑥
                     (1)                                                                                                                                                                                        
2-7: Monomer-Dimer Model 
We consider a monomer-dimer model to describe the equilibrium between monomers and dimers 
as follows: 
                     m+m 
𝐾
↔ D                            (2) 
Here (m) denotes monomers and (D) denotes dimers.  
The equilibrium association constant (K) can be written as follows for the above reaction: 
                                                                       𝐾 =  
[𝐷]
[𝑚]2
                                   (3) 
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The concentration of monomers [m] can be written in terms of the equilibrium constant and the 
total concentration. First we solve for the fraction of monomers(𝑓𝑚 ): 
                                        𝑓𝑚 =
1
1+2𝐾[𝑚]
                           (4) 
We know that the total concentration [T] can be written as: 
                                     [𝑇] = [𝑚] + 2[𝐷]                    (5) 
Substituting for [D], we write [T] as shown below: 
                                  [𝑇] = 𝑚 + 2[𝑚]2𝐾                       (6) 
We can use the quadratic equation to solve for the concentration of monomers [m]: 
                             [𝑚] =
√1 + 8𝐾[𝑇] − 1
4𝐾
                        (7) 






                        (8) 
Next, we use the fact that the fraction of dimers plus the fraction of monomers is equal to 1, and 
calculate the fraction of dimers fd as:  
                               𝑓𝑑 = 1 − 𝑓𝑚 =
√1+8𝐾[𝑇]−1
√1+8𝐾[𝑇]+1
                    (9) 
The apparent FRET (Eapp) due to dimer formation can be calculated as: 
                                                𝐸𝑎𝑝𝑝 = 𝑓𝑑𝑥𝐴  Ẽ                     (10) 
Note that when the dimeric fraction is 100% (fD=1), equation (2) reduces to 
                                                            𝐸𝐷 = 𝑥𝐴Ẽ                         (11) 
The equations above give us the relations needed to calculate the interaction parameters. The 
fraction of acceptors (xA) is calculated by dividing the number of acceptors (A) by the total 
number of receptors (T) as: 
                                                                    𝑥𝐴 =
𝐴
𝑇
                      (12) 
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We use intrinsic FRET (Ẽ), which comes from fitting the model to the data, to calculate the 
distance between two fluorophores in the dimers as described below: 





6                       (13) 
The Förster radius (R0) is unique to each donor/acceptor pair. The above equation uses Ẽ and R0 
to yield the distance (d) between two fluorophores. In all cases, R0 of 54.5Å is used to calculate 
the distance between two fluorophores attached to the Trk receptor in the plasma membrane.  
Data fitting and analysis was performed by utilized a computationally-derived library of 
proximity FRET efficiencies that were simulated over a finite grid of equilibrium constant, K, 
and Ẽ values, for acceptor concentrations ranging from zero to 8 × 103 acceptors/μm2, and for 
three different exclusion radia: 1 nm, 1.4 nm, and 2 nm [10]. In the first step of the fitting 
procedure, this proximity FRET library was used to perform a gridded search for the best-fit K 
and Ẽ from the library, by calculating the total FRET efficiencies and comparing them to the 
experimentally measured ones. Since small changes to these parameters have little effect on the 
magnitude of the proximity FRET contribution, in the second step we fixed the proximity 
contribution and we calculated the FRET efficiencies that are due to specific dimerization, ED, 
using equation. We then fit a monomer-dimer model to the corrected FRET data while varying 
Kdiss and Ẽ, using a MATLAB non-linear least squares algorithm to find the best-fit values of 
Kdiss and Ẽ and their 66% confidence intervals.  
The stability of the dimer is related to the dissociation constant according to  
            𝛥𝐺 = 𝑅𝑇 ln (
𝐾𝑑𝑖𝑠𝑠
106
⁄ )                         (14)  
with Kdiss reported in units of receptors per m2, and the standard state for ΔG calculation 
defined as 𝐾𝑑𝑖𝑠𝑠
0 = 1 rec/nm2 [12] 
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2-8: Analysis of Variance (ANOVA)-Test  
We performed one-way analysis of variance (ANOVA) to compare dimerization 
parameters for Trks in the absence and presence of ligands. The null hypothesis was tested that 
the dimerization parameter values are the same for the Trk receptors. A multiple comparisons 
test was performed to identify statistically significant differences among dimerization 
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Chapter 3: Dimerization of the Trk receptors in the plasma 
membrane: effects of their cognate ligands 
This article was published in the Biochemical Journal. The text here is revised to match the 
thesis submission requirement.  
Ahmed, Fozia, and Kalina Hristova. "Dimerization of the Trk receptors in the plasma membrane: 
effects of their cognate ligands." Biochemical Journal 475.22 (2018): 3669-3685. 
3-1: Introduction 
RTKs, the second largest family of membrane receptors, are known to control cell 
growth, differentiation, and motility via lateral dimerization in the membrane. Their 
dysregulation has been linked to many human diseases and disorders, including a variety of 
cancers [1][2][3][4].  There are 58 different RTKs in humans, grouped in 20 different families, 
which all share the same basic architecture:  an N-terminal extracellular (EC) region, a single-
pass transmembrane (TM) domain, and an intracellular (IC) region containing a tyrosine kinase 
domain [5]. The RTK ligands are polypeptides often referred to as “growth factors.” The ligands 
bind to the RTK EC regions and activate the kinases, via a process that involves their cross-
phosphorylation on specific tyrosine residues. The activated kinases then phosphorylate 
additional tyrosines that serve as docking sites for adaptor proteins. The adaptors, in turn, bind 
cytoplasmic substrates and trigger downstream signaling pathways [1][6][7][8][9][10], such as 
the MAPK, PI3K, PKC, and STAT cascades which impact growth, development, and disease 
progression. 
Work during the last decade has provided evidence that RTK dimerization is required, 
but is not sufficient, for RTK activation. Instead, there also exist structural requirements for 
cross-phosphorylation to occur [2][11][12][13].  In particular, it has been proposed that a specific 
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orientation of the kinase domains in the dimer is required, and this optimal orientation is 
achieved only upon ligand binding, as a result of structural rearrangements that propagate along 
the length of the RTK[14][15][16].This view is supported by experiments which show that the 
TM domain dimer conformation changes upon ligand binding, correlating with an increase in 
receptor phosphorylation [17][18] Furthermore, the rotation of the TM dimer interface has been 
shown to lead to periodic oscillations in kinase activity, suggesting that the TM dimer structure is 
sensed by the kinases [19]. 
An alternate view exists, however, that ligand-induced structural changes cannot be 
propagated along the length of the RTK because the linkers between the different domains are 
unstructured [20]. In support of this view, there are data suggesting that the EC and IC domains 
can change conformations independently of each other [21][22]. There is also structural evidence 
for a loose connection between the EC and TM domains [22][23]. Within this conceptual 
framework, the main role of the ligand is to increase the stability of the RTK dimer  
[24].  Thus, there is no consensus on the mechanism of RTK activation by their ligands, even after 
decades of RTK research.  
Here, we investigate the interactions that regulate the behavior of the three RTKs from the 
Tropomyosin Receptor Kinase (Trk) family in the plasma membranes of mammalian cells. The 
Trk receptors are expressed in neuronal tissues, and they guide the development of the central and 
peripheral nervous systems [25][26][27]. They also play a profound role in disease, such as cancer 
and neurodegeneration [28][29][30]. The Trk receptors share a high degree of structural homology, 
and their extracellular domains are all composed of three leucine-rich motifs flanked by two 
cysteine-rich clusters at the N-terminus, followed by two Ig-like domains linked to the TM 
segment. The ligands of the Trk receptors are called neurotrophins. They bind to the second Ig-
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like domain closest to the membrane, and trigger downstream ERK, PI3K and PLC- signaling 
pathways that control differentiation, proliferation, and survival of neurons [31][32][33][34]. 
The biology of the Trk receptors has been studied extensively, because of their important 
physiological roles [25][26][35]. However, the biophysical principles behind Trk receptor 
dimerization and activation in response to their ligands have not been elucidated. We characterize 
the homodimerization of the three Trk receptors in the plasma membrane, as well as their response 
to their cognate ligands (hß-NGF in the case of Trk-A, h-BDNF in the case of Trk-B, and h-NT-3 
in the case of Trk-C). We do this with the help of a FRET-based methodology that can give 
quantitative information about RTK dimerization, and can report on structural changes that occur 
in the RTK dimer upon ligand binding [36][37][38][39]. 
3-2: Results 
Full length Trk-A forms dimers in the plasma membrane, in the absence of ligand 
To study Trk receptor dimerization using FRET, we attached either mTurquoise or eYFP 
(a FRET pair) to the C-terminus of full length Trk-A (Figure 2-2). Then, we co-transfected HEK 
293T cells with 2 ug of DNA encoding for Trk-A-mTurquoise and Trk-A-eYFP, while varying 
the ratios of the two plasmids. After the receptors were trafficked to the plasma membrane, the 
cells were starved for 12 hours to remove all ligands, and imaged in a two photon microscope 
equipped with the OptiMiS spectral detection system [39][40].  Images were acquired and 
processed using the fully quantified spectral imaging (FSI) methodology, which involves the 
acquisition of two complete spectra: a FRET spectrum collected upon donor excitation, and an 
acceptor spectrum collected upon acceptor excitation [39]. As discussed in details in previous work 
[39], the FSI methodology yields FRET efficiencies and receptor concentrations in the plasma 
membrane with high precision, and can thus yield dimerization curves.  
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It is a challenge to measure the two-dimensional (2D) concentration of membrane proteins 
in the plasma membrane, because cells possess two to three times the membrane surface needed 
to sustain their shape and thus the plasma membrane is highly “wrinkled” or “ruffled” [41][42]. 
While the effective 3D receptor concentrations can be determined by comparing the fluorescence 
intensities with standard solutions of fluorescent proteins of known concentrations [37][38], the 
complex membrane topology prevents their conversion into 2D receptor concentrations within the 
plasma membrane [43]. However, cell membranes can be “un-wrinkled” in a reversible manner 
when the cells are subjected to controlled osmotic stress which leads to the disassembly of the 
caveolae [44]. The application of the reversible stress does not alter the FRET efficiencies [45], 
indicating that membrane protein interactions are not altered in a measurable way. The reversible  
stress does not cause irreversible cell damage, either [46],[47]. In the cells under reversible osmotic 
stress, we analyzed membrane regions of homogenous fluorescence, about 3 m in length, using 
the FSI software [39]. We calculated three parameters for each of the regions: the donor 




Figure 3- 1: FRET data for full-length Trk-A in the absence of ligand. (A) FRET efficiencies as a 
function of acceptor (Trk-A-eYFP) concentration. Every data point has different donor (Trk-A-
mTurquoise) concentration.  (B) Donor (Trk-A-mTurquoise) concentration, plotted as a function 
of acceptor (Trk-A-eYFP) concentration. (C) Fraction of Trk-A dimers as a function of total Trk-
A concentration. The experimentally determined dimeric fractions are binned and are shown 
with the symbols, along with the standard errors. The solid line indicates the best-fit dimerization 







The Trk-A FRET data, for the case of the 1:3 donor-to-acceptor transfection ratio, is shown in 
figure 3-1. Figure 3-1-A shows the FRET efficiencies as a function of acceptor concentration. 
Figure 3-1-B shows the donor versus the acceptor concentration in each region. Since each data 
point is derived from one cell, Figure 3-1-B demonstrates that the analyzed cell pool exhibits a 
substantial variation in the donor-to-acceptor ratio and the total receptor concentration (donor + 
acceptor expression) despite the fact that transfection is always performed under identical 
conditions. This heterogeneity is embraced and exploited in the FSI-FRET method, as it enables 









Figure 3- 2: FRET and cross-linking data demonstrating full-length Trk-A dimer-formation. (A) 
Histograms of measured FRET efficiencies at four different donor to acceptor ratios (1:2, 1:3, 
1:4, and 1:5). (B) Histograms of acceptor fractions (xA) for the four donor to acceptor ratios. (C) 
Average FRET efficiencies as a function of average acceptor fractions (xA). The standard errors, 
which are smaller than the symbols, are also shown.  The linear dependence is indicative of 
dimer formation. (D) Trk-A Western blot in the absence and presence of a chemical cross-linker. 
Lane 1: Trk-A; Lane 2: Trk-A + cross-linker; Lane 3: Trk-A + hß-NGF + cross-linker.  The 
molecular weight of monomeric, mature, fully glycosylated TrkA is ~ 140 kDa, and thus the 
molecular weight of fully mature Trk-A-YFP is ~170 kDa. The intense lower molecular weight 
band corresponds to immature, partially glycosylated TrkA found in the ER and Golgi. The fully 
mature Trk-A-YFP dimer molecular weight is ~340 kDa. 
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Most RTKs are known to form dimers, and we investigated if this is the case for Trk-A by 
examining the dependence of the FRET efficiency on the acceptor fraction. In this type of analysis, 
the dependence of the FRET efficiency on the acceptor fraction is known to be linear for a dimer 
and nonlinear for higher order oligomers [47], [51], [52], [53].  To investigate this dependence, we 
analyzed the FRET efficiencies measured for four different Trk-A-mTurquoise to Trk-A-eYFP 
DNA transfection ratios: 1:2, 1:3, 1:4, and 1:5 (shown in Figure 3). Histograms of FRET 
efficiencies and fractions of acceptor-labeled receptors are shown in Figure 3-2-A and 3-2-B for 
the four different transfection ratios.  These histograms were fitted to Gaussian functions to obtain 
the averages and the standard errors. The average FRET efficiencies obtained from the histograms 
are plotted versus the average acceptor ratios in Figure 3-2-C for the four DNA transfection ratios 
(symbols; standard errors are also shown but they are smaller than the symbols). The data in Figure 
3-2 are well described by a linear function (R2=0.995), suggesting that Trk-A forms dimers in the 
absence of ligand.  
To confirm dimer formation, we performed cross-linking experiments with Trk-A-eYFP 
in the presence and absence of its ligand hß-NGF. In these experiments, cells expressing Trk-A-
eYFP were incubated with a cross-linker, lysed, and subjected to Western blotting. Since in the 
cross-linking experiments we do not monitor the 2D concentrations of the receptors in the 
membrane, no application of reversible osmotic stress was required. Trk-A bands were visualized 
using anti-GFP antibodies. Results, shown in Figure 3-2-D, reveal two monomeric bands: one at 
molecular weight ~170 kDa, corresponding to mature, fully glycosylated Trk-A-YFP, and one at 
~140 kDa, corresponding to immature, partially glycosylated Trk-A-YFP found in the ER and the 
Golgi [54], [55]. The dimer band for the fully glycosylated Trk-A-YFP is expected to be at ~340 
kDa, and indeed we see such a band in the presence of the cross-linker. These results support the 
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idea that Trk-A forms a dimer, in the absence and presence of ligand, and are consistent with the 
literature [56]. Note that the immature band is not cross-linked because it is not localized to the 
plasma membrane (as the cross-linker is membrane-impermeable), and thus does not contribute to 
the measured FRET in figures 3-1 and 3-2. 
Next, we sought to interpret the FRET data in figure 3-2 within the framework of a 
thermodynamic model of dimerization as described previously [43]. Dimer formation can be 
characterized by two parameters: the two-dimensional dissociation constant, Kdiss, and the 
structural parameter Ẽ (or “Intrinsic FRET”). The dissociation constant, Kdiss, is a measure of the 
dimerization propensity of Trk-A in the plasma membrane. The Intrinsic FRET is the FRET 
efficiency in a Trk-A dimer with one donor and one acceptor. It depends on the positioning of the 
fluorescent proteins within the Trk-A dimer, but not on the dimerization propensity [17], [37]. To 
interpret the FRET data, we further took into account that the measured FRET in the membrane 
has two contributions: one due to Trk-A dimerization and one due to the confinement of the mobile 
fluorophores in the two-dimensional membrane [57],[43]. The latter FRET occurs because of the 
random close approach (within 100 Å) of the donors and acceptors in the plasma membrane.  This 
“proximity FRET” contribution is well understood, and can be corrected for as discussed in detail 
elsewhere [57], [43], [58]. The best-fit Kdiss and the best-fit Intrinsic FRET are determined from 
the FRET data while accounting for proximity FRET, following a verified two-step fitting protocol 
that is briefly described in Materials and Methods (see also [58]). The dimeric fraction of Trk-A 
as a function of the total Trk-A concentration is shown in Figure 2C.  We see that Trk-A exhibits 
a significant dimer population in the absence of ligand. The solid line in Figure 2C shows the 
dimerization curve calculated for the best-fit value of Kdiss. The solid symbols show the 
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experimentally derived dimeric fractions, which have been binned into 30 bins over the expression 
range of Trk-A, and then averaged within the bins.   
The optimal values of Kdiss and Intrinsic FRET, as well as their 66% confidence intervals, 
are given in Table 3-1.  The two dimensional dissociation constant for the Trk-A receptor, Kdiss, is 
132 ± 0.37 receptors/µm2, and the corresponding dimerization free energy is -5.30 ± 0.17 




































Table 3- 1:  Dimerization parameters for the three full-length Trk receptors, in the absence of 
ligand and in the presence of 380 nM ligand. Kdiss is the two-dimensional dissociation constant, 
a thermodynamic parameter, which is related to the stability of the Trk dimers, ΔG, according to 
equation 14. Ẽ is the Intrinsic FRET, which depends on the positioning of the fluorescent 
proteins within the Trk dimers. The average distance between the fluorescent proteins, d, is 
calculated from Ẽ using equation 13, under the assumption for free rotation of the fluorescent 






Figure 3- 3: Dimerization curves for the three full-length Trk receptors in the absence of ligands. 




















Full length Trk-B and Trk-C receptors form dimers in the plasma membrane, in the 
absence of ligand 
We performed similar experiments with full-length Trk-B and Trk-C, labeled with either 
mTurquoise or eYFP at their C-termini via flexible (GGS)5 linkers. The dimerization curves, 
obtained as described above, are shown in figure 3-3, and are compared to the Trk-A results. The 
two parameter fit to the Trk-C data reveals a dimerization constant that is similar to Trk-A, but the 
value of the Intrinsic FRET is higher (Table 3-1). Trk-B, on the other hand, exhibits much higher 
dimerization propensity, with Kdiss = 12 ± 2 rec/m
2. Overall, the data in figure 3-3 show that all 
three Trk receptors, and particularly Trk-B, homo-dimerize strongly in the plasma membrane, even 
in the absence of ligand. 
Thermodynamic contributions of Trk domains to unliganded dimerization 
In order to gain insight into the contributions of the different domains to the stability of the 
unliganded Trk-A dimer, two truncated versions of the Trk-A receptor were created.  First, the  IC 
domain was removed to generate a Trk-A ECTM construct containing the EC and TM  domains, 
with the fluorescent proteins attached to the TM domains via a 15 amino acid (GGS)5 flexible 
linkers [59], [60] (see Figure 2-2). In the second truncated version of the Trk-A receptor, both the 
IC and EC domains were removed to generate the TM Trk-A construct, with the fluorescent 
proteins attached to the TM domain C-terminus by the same 15 amino acids (GGS)5 flexible linker  
(Figure 2-2).  The FSI method was used to characterize the dimerization of the two 




Figure 3- 4:  FRET data for the ECTM Trk receptors, which lack IC domains, and for the TM 
Trk receptors, which lack both EC and IC domains. Data are collected in the absence of ligand. 
(A, D, and G) Measured FRET efficiencies as a function of receptor concentrations. (B, E, and 
H) Donor concentrations versus acceptors concentrations. (C, F, and I) Dimeric fractions as a 
function of total receptor concentrations.  The experimentally determined dimeric fractions are 
binned and are shown with the symbols, along with the standard errors. The solid lines are the 
dimerization curves, plotted for the optimized dimerization parameters reported in Table 3-2.  








Table 3- 2: Dimerization parameters for the three truncated Trk receptors, in the absence of 
ligand and in the presence of 380 nM ligand (n.s.  not statistically significant; ****p-Value 


































Figure 3-4-A shows FRET as a function of acceptor concentration for the ECTM and TM 
Trk-A constructs. Figure 3-4-B shows the donor versus the acceptor concentration for these 
constructs. Figure 3-4-C compares the dimerization curves for the ECTM and TM constructs with 
the dimerization curve for the full length Trk-A receptor. The calculated best-fit parameters for 
these constructs are reported in Table 3-2. According to these results, the removal of the IC domain 
decreases the dimer stability from -5.30 ± 0.17 to -3.65 ± 0.08 kcal/mole, indicating that contacts 
involving the IC domains stabilize the full-length Trk-A dimer. The removal of the EC domain, 
however, has no effect on dimer stability, as the ECTM and TM free energies of dimerization are 
the same, -3.65 ± 0.08 and -3.61 ± 0.09 kcal/mole, respectively. Thus, Trk-A dimerization in the 
absence of ligand occurs because of stabilizing contacts between the TM and IC domains, without 
a significant contribution from the EC domain. 
We performed similar experiments with the truncated versions of Trk-B and Trk-C. Figures 
3-4-D and 3-4-G show FRET as a function of acceptor concentration. Figures 3-4-E and 3-4-H 
show the donor versus the acceptor concentration for these constructs. Figures 3-4-F and 3-4-I 
compare the dimerization curves for the ECTM and full-length receptors. According to the best-
fit parameters in Table 3-1 and Table 3-2, the removal of the IC domain in Trk-B decreases the 
dimer stability from -6.72 ± 0.10 to -3.68 ± 0.04 kcal/mole, while the IC domain in Trk-C has no 
significant effect on dimerization. Of note, attempts to fit the FRET data for the Trk-B and Trk-C 
TM constructs with a dimer model were unsuccessful, suggesting that these TM domains form 
oligomers in the plasma membrane.   
Effect of ligands on Trk dimerization 
Neurotrophins interact with the Trk receptors to initiate downstream signaling [25][31] 
[61]. Here we studied how Trk dimerization is affected by three ligands, hß-NGF, h-BDNF, and 
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h-NT-3, which are known as cognate ligands for Trk-A, Trk-B, and Trk-C, respectively.  The 
ligand binding affinities have been characterized previously using different methods, and 



















Figure 3- 5: FRET data for full-length Trk receptors in the presence of ligand at saturating 
concentration. (A) FRET as a function of acceptor concentration for Trk-A in the presence of hß-
NGF. (B) Trk-A-mTurquoise (donor) concentration versus Trk-A-eYFP (acceptor) concentration 
in the presence of hß-NGF. (C) Fraction of dimers as a function of total receptor concentration 
for Trk-A, Trk-B and Trk-C in the presence of hß-NGF, h-BDNF and h-NT-3, respectively. (D) 
Histogram of Trk-A Intrinsic FRET values in the presence of hß-NGF. (E) Histogram of Trk-B 
Intrinsic FRET values in the presence of h-BDNF. (F) Histogram of Trk-C Intrinsic FRET values 
in the presence of h-NT-3. The dimerization parameters for the three receptors in the presence of 









We sought to carry out FRET experiments under well-defined conditions, when all the Trk 
receptors are ligand-bound.  We therefore performed the FRET experiments in the presence of 5 
ug/ml (~ 380 nM) of each ligand, which greatly exceeds the reported dissociation constants.  The 
FRET and concentration data for Trk-A in the presence of hß-NGF are shown in Figures 3-5-A 
and 3-5-B. The dimerization curves (dimeric fractions as a function of total Trk concentration) for 
the three Trk receptors are shown in Figure 3-5-C in the presence of their respective ligands.  We 
see that the Trk receptors are 100% dimeric over the concentration range sampled in the 
experiments.  Thus, the two-dimensional dissociations constants are very low and could not be 
measured. The results demonstrate that hß-NGF, h-BDNF, and h-NT-3 stabilize the Trk-A, Trk-
B, and Trk-C dimers, respectively.  
In the case of 100% dimers, the Intrinsic FRET is calculated for each cell using equation 
11.  Note that both the FRET efficiencies and the acceptor fractions, xA, are directly measured with 
the FSI-FRET method, and thus no fitting was required for these calculations. The Intrinsic FRET 
values from individual cells are shown as histograms in Figures 3-5D, E and F, for Trk-A, Trk-B, 
and Trk-C, respectively, and are fit with Gaussian functions. The Gaussian fit parameters are 
shown in Table 3-1.  Comparison of the Intrinsic FRET values in Table 3-1 with and without ligand 
reveals a large change in Intrinsic FRET for Trk-C upon the addition of h-NT-3, but no significant 
effects for Trk-A and Trk-B in response to hß-NGF and h-BDNF, respectively. As the fluorescent 
proteins are attached to the C-termini via flexible linkers, the differences in Intrinsic FRET for 




Figure 3- 6: Dimerization curves for ECTM Trk-A, Trk-B and Trk-C in the presence and absence 
of ligands. (A) ECTM Trk-A in the presence and absence of hß-NGF. (B) ECTM Trk-B in the 






























To gain additional insights into the effect of the three ligands on Trk dimerization, we 
performed FRET experiments with the truncated ECTM Trk constructs with deleted kinase 
domains, in the presence of ligands. The dimerization curves for the ECTM Trk receptors in the 
presence of saturating concentrations of their cognate ligands are shown in Figure 3-6 and are 
compared to the curves in the absence of ligand. The best fit dimerization parameters are shown 
in Table 3-2.  Inspection of Figure 3-6 and Table 3- 2 shows that the cognate ligands stabilize the 
ECTM Trk dimers. 
As the deletion of the IC domains decreases Trk dimerization, we are able to quantify the 
stabilities of the ligand-bound Trk dimers and to calculate the respective dissociation constants 
(see Table 3-2). This allows us to determine the effect of the bound ligands on the thermodynamic 
stabilities of the dimers, by subtracting the ECTM dimer stabilities with and without ligand.  We 
see that hß-NGF, h-BDNF, and h-NT-3, at 380 nM, stabilize the Trk-A, Trk-B, and Trk-C dimers 
by -2.63 ± 0.14 kcal/mole, -2.65 ± 0.10 kcal/mole, and -1.49 ± 0.17 kcal/mole, respectively.  
Table 3-2 shows the Intrinsic FRET values for the liganded truncated ECTM Trk dimers, 
determined from the fit of a monomer-dimer model to the measured FRET data. When we compare 
these values to the values in the absence of ligand, we see significant differences in the cases of 
Trk-A and Trk-B. As the fluorescent proteins are attached directly to the TM domains via flexible 
linkers, the changes in Intrinsic FRET likely reflect changes in the distance between the C-termini 









Using a FRET-based quantitative technique, we showed that the Trk receptors form dimers 
not only in the presence of ligand, but also in the absence of ligand. Our results are consistent with 
the literature [56][68][69], and yield the first measurements of Trk dimer stabilities. The Trk 
dissociation constants in the unliganded case, which vary from 12 to 227 rec/m2, can be compared 
to the dissociation constants measured previously for the FGFRs— varying from 24 rec/m2 (for 
FGFR3) to 710 rec/m2 (for FGFR1) [17]—and for VEGFR2—35 rec/m2 [18]. Thus, the Trk 
receptor propensities for unliganded dimerization are similar to those of other characterized full 
length RTKs.  
The estimates of Trk-A expression in the membrane of PC12 cells are ~20 Trk-A rec/m2 
[69], [70]. Since the measured Trk-A dissociation constant is 132 ± 37 rec/m2, about 20% of the 
Trk-A molecules are expected to be dimeric in PC12 cells in the absence of ligand.  Notably, Trk-
A expression in PC12 cells is similar to the measured Trk-B dissociation constant, 12 ± 2 rec/m2. 
This suggests that unliganded Trk dimerization is important in physiological contexts.   
To gain insight into factors that determine the stability of the unliganded Trk dimers, we 
measured the thermodynamic contributions of the different Trk domains to unliganded 
dimerization (Figure 3-4). The contributions of the IC domains of Trk-A and Trk-B to dimer 
stabilities are favorable, since the deletion of the IC domains significantly destabilized the Trk-A 
and Trk-B dimers. However, the contribution of Trk-C IC domain is practically zero, suggesting 
that either Trk-C IC domain does not engage in contacts that stabilize the full-length Trk-C dimer, 
or these stabilizing contacts are balanced by repulsive ones. This finding is reminiscent of the case 
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of the FGFRs, where the IC domains of FGFR2 and FGFR3 contribute to dimer stabilization, but 
the FGFR1 IC domain has no effect [17].  
By measuring the dimerization of the TM Trk-A construct and comparing it to the ECTM 
Trk-A construct, we showed that the contribution of Trk-A EC domain to unliganded dimerization 
is negligible. This result is different from observations for other RTKs such as the FGFRs and 
VEGFR2, where removal of the EC domain increases dimer stability [17], [18], thus indicating 
that the EC domains of those other receptors inhibit dimerization in the absence of ligand.  A 
crystal structure of the hß-NGF-bound isolated Trk-A EC domain shows that the ligand-bound 
dimer is stabilized exclusively through hß-NGF-TrkA contacts, but not through direct Trk-
A⸺Trk-A contacts [71]. Accordingly, it appears that there are no direct interactions between Trk-
A EC domains that contribute to dimer stability, both in the absence and presence of the hß-NGF 
ligand. The Trk-A dimers are instead stabilized through contacts between the TM domains and the 
IC domain. 
Unlike in the Trk-A case, we were not able to determine the thermodynamic contribution 
of Trk-B and Trk-C EC domains to unliganded dimerization, because we could not fit the FRET 
data for TM Trk-B and TM Trk-C with a dimer model. Thus, these TM domains likely form 
oligomers that are larger than dimers. Despite the propensity of these TM domains to oligomerize, 
it can be expected that the bulky Trk-A EC and IC domains impose constraints that do not allow 
three or more TM helices to interact closely, thus preventing higher order oligomerization for the 
full-length receptors.  These observations underscore the limitations of studying RTK TM domains 
in isolation, outside the context of full-length RTKs. Indeed, NMR studies of isolated RTK TM 
domains in detergent have revealed that the TM domains can form trimers, which are likely 
irrelevant in biological context [72].  
55 
 
In this work we also sought to measure the effect of ligand binding on RTK dimer stability. 
It is known that bound ligands stabilize RTK dimers, but the exact contribution of ligand binding 
to RTK dimer stability has not been measured. Usually the stabilities of the ligand-bound RTK 
dimers are too high, precluding calculations of the dissociation constant, as also demonstrated here 
for the three full-length Trk receptors.  Since the deletion of the kinase domains decreased the 
stabilities of the Trk dimers, however, the dissociation constants became measurable for the ligand-
bound truncated ECTM Trk dimers. We were thus able to show that the contributions of the three 
ligands to Trk dimer stability varies from ~-1.5 to ~-2.5 kcal/mole, at 380 nM ligand. To the best 
of our knowledge, this is the first direct measurement of the energetics behind RTK dimer 
stabilization by a ligand. 
Along with dimer stabilities, we quantified the Intrinsic FRET for all studied Trk dimers, 
both in the absence and presence of their cognate ligands. Intrinsic FRET is a structural parameter 
that depends on the distance between the fluorescent proteins and on their relative orientation, but 
does not depend on dimer stability. We used Intrinsic FRET to follow structural changes that occur 
on the cytoplasmic side of the receptor upon ligand binding to the extracellular domains. We 
characterized full-length constructs, where the fluorescent proteins were attached to the C-termini 
of the receptors via flexible, 15-residue (GGS)5 linkers. We also characterized truncated ECTM 
Trk constructs, in which the fluorescent proteins were attached to the TM domains via flexible, 
15-residue (GGS)5 linkers. 
We observed that the Intrinsic FRET value for full-length Trk-C changes upon ligand 
binding (Table 3-1). Since the fluorescent proteins are attached to the C-termini via flexible 
linkers, the measured change is indicative of a change in the relative positioning of the C-termini 
in response to ligand. We further observed that the Intrinsic FRET for ECTM Trk-A and Trk-B 
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changes upon ligand binding.  Since in this case the fluorescent proteins are attached to the C-
termini of the TM domains via flexible linkers, differences in Intrinsic FRET are indicative of 
changes in the relative positioning of the TM C-termini upon ligand binding. 
The linkers used to attach the fluorescent proteins to the Trk receptors have been shown 
previously to behave as random coils [59]. If the orientation of the fluorescent proteins at the end 
of the linkers is random, the Intrinsic FRET will depend primarily on the distance between the 
fluorescent proteins in the Trk dimers, as shown in equation 13. In Tables 3-1 and 3-2, we calculate 
the distances between the fluorescent proteins under the assumption of random orientation of the 
fluorophores, an assumption which may not be entirely correct. Even if the exact distances are not 
precisely accurate, the relative changes in fluorescent protein separation due to ligand binding 
should still hold true. These distances allow for visualization of the conformational changes that 




Figure 3-7. The three Trk receptors undergo conformational changes in the IC region after their 
cognate ligands bind to their extracellular domains. Top: Schematic depiction of the changes 
occurring in Trk-A and Trk-B. The TM domain C-termini move apart upon ligand binding, while 
the distance between the C-termini of the receptors does not change in a significant way.  Bottom:  
Schematic depiction of the changes occurring in Trk-C in response to ligand binding. The C-
termini move apart upon ligand binding, but the average distance between the TM domain C-






A cartoon illustrating the change in these distances is shown in Figure 3-7. In the top 
panel we depict the changes occurring in Trk-A and Trk-B in response to ligand binding. We 
show that the TM domain C-termini move apart upon ligand binding, while the distances 
between the C-termini of the receptors do not change in a significant way. This implies 
conformational changes in the Trk-A and Trk-B IC domain dimers upon ligand binding.  In the 
bottom panel, we depict the Trk-C case, where the average distance between the TM domain C-
termini does not change in a significant way, but the C-termini move further apart. This also 
implies conformational changes in the Trk-C IC domain dimer upon h-NT-3 binding. While the 
nature of the ligand-induced changes are different in the cases of Trk-A and Trk-B, on one hand, 
and Trk-C, on the other, the data suggest that all three Trk receptors undergo conformational 
changes in the IC region after their cognate ligands bind to their extracellular domains. These 
changes are likely critical for signal propagation across the plasma membrane. 
3-4: Implications 
Two RTK activation models have been widely discussed in the literature: (1) the 
“diffusion-based” or or “canonical” model , which postulates that RTKs dimerize and activate each 
other only upon ligand binding (but have no propensity to interact with each other and are always 
monomeric in the absence of ligand [1],[5], and (2) the “pre-formed dimer model,” in which RTKs 
form constitutive dimers, which get activated in response to ligand binding [6][11][20][56][12]. 
However, quantitative measurements of dimerization, such as the ones described here, reconcile 
these seemingly contradictory models.  Indeed, here we find that the measured dissociation 
constants vary for the different Trk receptors, even though they belong to the same receptor family. 
Depending on the exact value of the two-dimensional dissociation constant and the expression 
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levels, RTKs may appear to be predominantly monomeric or predominantly dimeric at a specific 
expression level, in accordance with the law of mass action.  
An important role of the ligand in the pre-formed dimer model  is to induce a structural 
change in the RTK dimer that reorients the catalytic domains for efficient activation 
[73][12][13][17][18]. However, this role has been recently challenged because the linkage between 
the different RTK domains has been proposed to be flexible [24]. If this is the case, the different 
domains are not structurally coupled, and thus structural information cannot be propagated along 
the length of an RTK. Resolving this controversy is challenging, as there are experimental 
limitations in following conformational changes in the intracellular domains of RTK dimers upon 
ligand binding to their EC domains, especially in the context of the full length receptors in the 
plasma membrane of live cells. Here, we provide evidence of conformational changes in the 
intracellular portions of the Trk dimers through measurements of Intrinsic FRET. The observed 
structural change ensures that the kinase domains adopt a signaling-competent orientation only 
upon ligand binding and can explain how RTKs which form very strong preformed dimers, such 
as Trk-B, can be activated by their ligands.   
Overall, this work supports a model of Trk activation in which (1) Trks have a propensity 
to interact laterally and to form dimers even in the absence of ligand, (2) different unliganded Trk 
dimers have different stabilities (and thus different dimer abundance at physiological 
concentrations), (3) ligand binding leads to Trk dimer stabilization and (4) ligand binding induces 
a structural changes in the Trk dimer. Thus, an increase in the expression level can cause a 
transition from predominantly monomeric to predominantly dimeric populations, even in the 
absence of ligand. When ligand binds to the unliganded dimers, it induces a transition to a 
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structurally distinct dimeric state with higher stability. This model views RTK activation through 
the lens of physical chemistry and we term it the “transition model of RTK activation.”  
It is tempting to speculate that all of the 58 RTKs follow the transition model of RTK 
activation. Alternatively, it is possible that no single model can capture the activation mechanism 
of all 58 RTKs. If this is the case, then the activation mechanism needs to be elucidated 
experimentally for every one of the 58 RTKs. The quantitative FRET methodology used in this 
work can help in this pursuit of basic knowledge about RTK activation. 
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Chapter 4: The molecular basis of receptor tyrosine kinase ligand 
functional selectivity: A Trk-B case study  
4-1: Introduction 
Receptors in the plasma membrane can bind multiple ligands and can initiate multiple 
downstream signaling cascades that control cellular physiology in health and disease. Recent 
work has uncovered that different ligands can selectively engage some signaling pathways over 
others and can lead to different biological outcomes while acting through the same receptor. This 
phenomenon is known as “ligand bias” or “ligand functional selectivity” and has been 
extensively characterized for the largest class of membrane receptors, the seven helix G-protein 
coupled receptors (GPCRs). The mechanism of ligand bias in GPCR signaling is now 
established: different GPCR ligands stabilize different functional receptor conformations, and 
each of the conformations triggers efficiently only a subset of the possible downstream signaling 
cascades. The discovery and the mechanistic studies of GPCR bias have redefined fundamental 
concepts in pharmacology, and have opened up new possibilities for the development of more 
effective and specific therapeutics.   
While most ligand bias investigations have focused on the GPCRs, ligand bias has also 
been observed for the second largest class of membrane receptors, the receptor tyrosine kinases 
(RTKs). RTKs are single-pass transmembrane proteins that control cell growth, differentiation, 
motility, and metabolism [1][2], by transducing biochemical signals via lateral dimerization or 
oligomerization in the plasma membrane. Their N-terminal extracellular (EC) regions, composed 
of characteristic arrays of structural domains, bind the activating ligands [3]. They have single 
transmembrane helices and intracellular kinase domains (Fig. 1). The cross-phosphorylation of 
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two kinase domains in the ligand-bound dimers and oligomers stimulates catalytic activity, 
which results in the phosphorylation of cytoplasmic substrates, ultimately activating signaling 
cascades that control cell behavior [2][4][5].   
It is now well documented that different ligands can induce different biological responses 
when binding and activating the same RTK [6][7][8][9][10][11][12][13][14]. There are reports 
of ligand bias involving the ERBB receptors [15], the fibroblast growth factor receptors (FGFRs) 
[7], and the Eph receptors[16]. However, the mechanism behind this ligand bias is not well 
understood for the RTKs, and is a subject of debate. Some studies have proposed that RTK 
ligand bias occurs through a mechanism that is analogous to the one used by the GPCRs, i.e. 
different RTK ligands stabilize different RTK dimer configurations, leading to differential kinase 
domains activity. Others, however, argue that the mechanism is fundamentally different, as RTK 
kinase domains cannot sense the identity of the bound ligand because the linkers between the 
different RTK domains are flexible. Rather, these researchers propose that the stability of the 
RTK dimer is the important parameter that controls ligand bias.  
Here we investigate the biophysical basis behind biased signaling by TrkB, an RTK that 
belongs to the three member Tropomyosin receptor kinases (Trks) family.  This family is 
characterized by extracellular domains that contain three tandem leucine rich repeats flanked by 
cysteine rich domains and two immunoglobulin-like domains [17][18]. The signaling cascades 
initiated by the Trk receptors control neuronal cell survival and proliferation, axonal and 
dendritic growth, as well as synaptic connections and synaptic plasticity 
[19][20][21][22][23][24]. Trk-B, studied here, plays a vital role in neural plasticity in early CNS 
development and in adulthood [25][18]. It is also present in non-neuronal cells such as glia and 
Schwann cells [26][27][28].  
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Trk-B signals in response to three different neurotrophins, h-BDNF, h-NT-3 and h-NT-4, 
which are small biological molecules with 50% sequence identity [29]. These neurotrophins play 
crucial role in the development, maintenance, and survival of neurons in both the peripheral and 
central nervous system [29][30]. Their binding to Trk-B leads to TrkB cross-phosphorylation and 
activation of downstream signaling. The main downstream signaling effectors which are 
activated by Trk-B are Ras mitogen activated protein kinase (MAPK), phosphotidylinositol 3- 
kinase (P13K), Akt, and PLCγ–Ca2 [31] . 
The three neurotrophins, ligands, h-BDNF, h-NT-3 and h-NT-4, have been reported to 
have similar binding affinities for Trk-B. There are also reports of similar Trk-B phosphorylation 
and activation in response to these ligands. Yet, these three neurotrophins can lead to different 
cellular responses when signaling through Trk-B. H-BDNF has been shown to play a much more 
profound role than h-NT-4 in synaptic transmission, plasticity, and in higher cognitive functions 
[32][33][25][34][35][36][37][38]. On the other hand, h-NT-4 is more potent at inducing neuronal 
survival and synaptic maturation [38][39]. In NIH3T3 cells, both h-BDNF and h-NT-4 are more 
potent than h-NT-3 in initiating growth responses [40][41].  
What factors could underlie the differential responses of Trk-B to the three 
neurotrophins? By analogy to the GPCRs, it can be expected that ligand bias starts with events at 
the plasma membrane.  It can be expected that either differences in the conformation of the 
kinase domains in response to the different ligands, or the stability of the ligand-bound dimers, 
or both, may be responsible. The conformations and the stabilities of the different neurotrophin-
bound Trk-B dimers have not been compared, however.  
In order to study protein interactions in the plasma membrane in quantitative terms, we 
have previously established a FRET-based assay that can yield RTK association constants and 
73 
 
can report on the occurrence of conformational changes upon ligand binding. Using this assay, 
we have previously shown that Trk-B forms a very stable dimer (Kdiss 
2(Chapter 
3)), even in the absence of ligand. The binding of h-BDNF to the pre-formed Trk-B dimer 
triggers a conformational change in the dimer and further enhances its stability. Here we 
investigate the response of Trk-B to h-NT-3 and h-NT-4, in order to compare it to the response to 
h-BDNF and thus gain insight into ligand functional selectivity. 
4-2: Results 
Here we use FRET to characterize the lateral interactions between Trk-B receptors, which 
are labeled with fluorescent proteins at the C-terminus (either mTurquoise or YFP, a FRET pair) 
via flexible (GGS)5 linkers, in the presence of two ligands, h-NT-3 and h-NT-4.  The cloning of 
the plasmids encoding for these constructs, and the FRET-based assessment of Trk-B interactions 
in the absence of ligand and in the presence of h-BDNF has been described in chapter 2 and chapter 
3.  
Experiments were conducted in the presence of 5µg/mL (380nM) h-NT-3 or h-NT-4 using 
the FSI-FRET method. The used ligand concentration is well above the reported ligand-receptor 
dissociation constants, which are in the pM to low nM range [28][41][42][43][33]. The FSI-FRET 
method, briefly described in chapter 2, yields three parameters: FRET efficiency, donor (Trk-B-
mTurquoise) concentration, and acceptor (Trk-B-YFP) concentration, in small patches of the 
plasma membrane of live cells.  Hundreds of individual cells, all expressing different amounts of 












Figure 4- 1: Comparison of FRET data for Trk-B in the presence of two ligands: h-NT-3 and h-
NT-4. A and C: FRET data as a function of acceptor concentration. The solid black line is the 
“proximity” FRET. B and D: donor vs. acceptor concentration for both ligands. E: proximity-
corrected FRET as a function of total Trk-B concentration. F: histograms of Trk-B FRET data in 
the presence h-BDNF, h-NT-3, and h-NT-4. G: dimerization curves for Trk-B in the absence and 





































Figures 4-1-A and 4-1-C show the FRET efficiencies in single cells as a function of the 
acceptor concentration in the presence of h-NT-3, and h-NT-4, respectively, while Figures 4-1-B 
and 4-1-D shows the donor concentration as a function of the acceptor concentration in the 
presence of the two ligands. In Figures 4-1-A and 4-1-C we also include the so-called “proximity” 
FRET which occurs due to the random close approach (within 100 Å) of the donors and acceptors 
confined to the two-dimensional plasma membrane.  The solid lines Figures in 4-1-A and 4-1-C 
show the best-fit proximity contributions, determined as described in chapter 2. The measured 
FRET is corrected for this “proximity” contribution following an established protocol [44][45][46] 
to obtain FRET due to specific Trk-B interactions, shown in Figure 4-1-E as a function of the total 
concentration. We see that the corrected FRET does not depend on the concentration, which 
indicates that Trk-B is constitutively dimeric over the concentration range that is accessible in our 
experiments. In this case the measured FRET in each cell region is proportional to the value of 
Intrinsic FRET (Ẽ, see equation 11), a structural parameter which depends on the positioning and 
dynamics of the fluorescent proteins attached to the C-termini of the receptors [47]. The histograms 
of Intrinsic FRET values, measured in the different cells for each receptor/ligand pair, are shown 
in Figure 4-1-F.  Also included in Figure 4-1-E are previously measured Intrinsic FRET values for 
Trk-B in the presence of 380 nM h-BDNF.  The three histograms are fit to Gaussian functions, and 
the mean and standard errors are shown in Table 4-1. Figure 4-1-E shows the binned dimeric 
fractions in the presence of the three ligands, as well as the dimeric fraction measured previously 
in the absence of ligand for Trk-B. Notably, Trk-B forms a very stable dimer even in the absence 






Table 4- 1: Comparing dimerization parameters for full length Trk-B receptor in the presence of 
three ligands (n.s.  not statistically significant; *p-value between 0.05 and 0.01;  ****p-Value 
































Taken together, the measured Intrinsic FRET values in Table 4-1 demonstrate that the 
distance and/or the orientation of the FPs, attached to the C-terminus of Trk-B, are different when 
the three different ligands are bound.  Note that for all ligands, we are interrogating 100% dimeric 
receptors (Figure 4-1-E), and thus the only difference in the experiments is the identity of the 
ligand that is bound to the EC domains. Therefore, the results suggest that the three ligands 
stabilize dimers with different intracellular domain conformations.  
To gain additional insights into the effect of the three ligands on Trk-B dimerization, we 
performed FRET experiments with a truncated ECTM Trk construct with deleted kinase 
domains. This construct contains the extracellular and transmembrane domains of Trk-B, a 15 





Figure 4- 2: ECTM Trk-B FRET data in the presence of the ligands h-NT-3 and h-NT-4. A and 
C: FRET as a function of acceptors for hNT-3 and h-NT-4, respectively. The solid black lines 
indicate the “proximity” FRET in A and C. B and D: plots for donor vs. acceptor concentrations 
for Trk-A in the presence of h-NT-3 and h-NT-4, respectively. E: proximity-corrected FRET 
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data for h-NT-3 and h-NT-4. F: Comparison of dimerization curves for Trk-B in the absence and 













































In Figure 4-2-A and 4-2-C we show the FRET efficiencies for the ECTM Trk-B construct 
in the presence of 380 nM of h-NT-3 and h-NT-4, measured for 200-500 individual cells, along 
with the optimized best-fit proximity FRET contribution. Figure 4-2-B and 4-2-D show the 
donor concentration versus the acceptor concentration for each of these cells, in the presence of 
h-NT-3 and h-NT-4. Figure 4-2-E shows the corrected FRET efficiency that is due to specific 
interactions between the ECTM Trk-B molecules, as a function of the total receptor 
concentration. Unlike in the case of full-length Trk-B, here the specific FRET increases as a 
function of the concentration. This indicates that Trk-B monomers and dimers coexist in the 
plasma membrane, and that the dimer population increases with the concentration as dictated by 
the law of mass action. A model of monomer-dimer equilibrium from chapter 2, was fitted to the 
data in Figure 4-2-E. The two unknown parameters in the fit were the dissociation constant, K, a 
measure of the strength of Trk-B interactions in the presence of 380 nM ligand, and the structural 
parameter Intrinsic FRET. The best-fit K and Intrinsic FRET values for ECTM Trk-B in the 
presence of the different ligands are shown in Table 4-2, along with previous results for the 
ligand h-BDNF. Figure 4-2-F shows experimental binned dimeric fractions in the presence of the 
three ligands, along with the best-fit.  For comparison, we also show the ECTM TrkB dimeric 



















Table 4- 2: Comparison of the dimerization parameters for ECTM-Trk-B construct (****p-Value 






























As seen in Figure 4-2-F and in Table 4-2, the stabilities of the three ligand-bound Trk-B 
dimers (at 380 nM ligand) are different. Furthermore, the Intrinsic FRET values measured in the 
presence of the three ligands are different. As the fluorescent proteins are attached to the TM 
domain C-termini via flexible linkers, these results suggest that the conformations of the Trk-B 
TM domain dimer are different when different ligands are bound to the EC domain. Thus, both the 


















































Figure 4- 3: Comparing the conformational differences in the TM and intracellular region of Trk-
B in the absence and presence of three ligands: h-BDNF, h-NT-3, and h-NT-4. A: Trk-B in the 
absence of any ligands. B: Trk-B in the presence of h-BDNF. C: Trk-B in the presence of h-NT-
3. D: Trk-B in the presence of h-NT-4. The three different ligands induce three different 
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In figure 4-3, Cartoon depiction is drawn for Trk-B in the absence and presence of three 
ligands to demonstrate changes in the conformation of the receptor bound to different ligands. In 
the presence all three ligands, there are changes in the conformation of Trk-B dimer which occur 
at the TM and C-termini regions of the receptor, suggestion each ligand is responsible for giving 
different dimer conformation. The stability of Trk-B dimer is also different for each ligand as 
reported in Table 4-2, thus, generating different downstream biological responses.  
4-3: Discussion 
Our understanding of RTK activation has been shaped, to a large degree, by crystal 
structures of isolated RTK EC domains in the absence and presence of their ligands. Crystal 
structures of EC domains bound to different activating ligands invariably show some structural 
differences [48][4][14].  However, it has been unknown if these differences are sensed by the 
kinase domains of the RTKs to lead to differential signaling outcomes [49][50][51][52].  
Two hypotheses have been discussed in the literature to explain the occurrence of RTK 
ligand bias. According to one hypothesis, ligand bias arises because the conformations of the 
kinase domain dimers are different when different ligands are bound to the extracellular 
domains.  According to this hypothesis, the conformational changes in the EC domain in 
response to the bound ligand are transmitted along the length of the RTK and reach the kinase. In 
support of this view, it has been shown that different ligands, bound to the same RTK, can 
induce different TM domain dimer conformations, or different conformations of the linker 
connecting the TM and kinase domains (the so-called JM domain).  Yet, there have been no 
direct demonstrations that the kinase domains can adopt distinct configurations when different 
ligands are bound to the EC regions. In part, this is due to experimental challenges to assess the 
conformation of the kinase domains inside cells when different ligands are bound to the EC 
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domain. Here we overcome the challenges by quantifying the so-called intrinsic FRET between 
the fluorescent proteins in the Trk-B dimer. We observe differences in Intrinsic FRET in the 
presence of h-NT-3, h-NT-4, or h-BDNF. These differences in Intrinsic FRET suggest 
differences in the relative positioning and/or dynamics of the FPs, and of the domains to which 
the FPs are attached. Therefore, our experiments reveal that the three ligands lead to different 
Trk-B intracellular configurations, in agreement with this ligand bias hypothesis. 
A second, seemingly alternative, hypothesis has been developed, prompted by 
observations that the EC and IC domains can change conformations independent of each other. 
Some believe that structural changes in the EC region cannot be propagated to the IC region, 
presumably because the linkers between the regions are unstructured. This second hypothesis 
postulates that the differential engagement of downstream molecules in response to different 
ligands is correlated with the thermodynamic stabilities of the ligand-bound RTK dimers in the 
plasma membrane. In particular, it has been proposed that RTK dimers with low stability fail to 
activate all downstream signaling pathways and to engage negative feedback mechanisms. To 
test if the Trk-B dimer has different stability when bound to h-NT-3, h-NT-4, or h-BDNF, we 
directly measure and compare the thermodynamic stability of Trk-B dimers at saturating 
concentrations of h-NT-3, h-NT-4, and h-BDNF.  We show that the stability of the ECTM Trk-B 
dimer is different when the three different ligands are bound. We could not measure 
thermodynamic stabilities for the full-length ligand-bound Trk-B because they were 100% 
dimeric in our experiments, due to favorable stabilizing interactions between the kinase domains. 
However, we expect that the differences observed for ECTM Trk-B hold true also in the 
case of full-length Trk-B.  Thus, overall our data are consistent with this second hypothesis about 
ligand bias. There is no reason for the two hypotheses, discussed above, to be mutually 
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exclusive. In fact, our work demonstrates that they are not. Indeed, we find here that each of the 
different ligands, h-NT-3, h-NT-4, and h-BDNF, stabilizes Trk-B dimers with different 
conformations and with different stabilities.  Furthermore, structure and stabilities can be 
expected to be correlated. 
This work gives new insights into the general mechanism behind ligand bias.  GPCRs 
transduce biochemical signals across the plasma membrane via conformational changes, and 
ligand bias occurs when different ligands induce different types of conformational changes.  For 
a long time, RTKs were believed to signal via a fundamentally different mechanism involving 
ligand-induced lateral dimerization. Recently it has become clear, however, that this simple 
model fails to capture all the complexities of RTK signaling and that the bound ligands need to 
induce conformational changes in RTK dimers for efficient downstream signaling to occur. 
Thus, both RTK dimer formation and conformational changes in the RTK dimer are required for 
RTK activation in the plasma membrane. Likewise, RTK ligand bias occurs due to both ligand-
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Chapter 5: Deciphering the mechanism behind hß-NGF and h-NT-3 
functional selectivity 
5-1: Introduction 
We have shown that Trk-A signals via lateral dimerization in the plasma membrane, 
which brings the two catalytic domains in close proximity, allowing them to cross-phosphorylate 
each other (data for dimerization of Trk-A shown in Chapter 3). The studies of Trk-A 
dimerization and changes in dimer conformation upon cognate ligand binding, hß-NGF, have 
shown that Trk-A forms dimers in the absence of ligand, and that ligand binding to the Trk-A 
dimer stabilizes the dimer further and causes a change in the dimer conformation [1]. 
Trk-A signaling is crucial for the development of the nervous system. The functioning of 
the nervous system relies on the establishment of precise neuronal circuits through a 
developmental program including neuronal proliferation, axonal growth and guidance, target field 
innervation, neuronal survival and synaptogenesis [2][3][4][5][6][7][8]. The neurotrophic growth 
factors such as Nerve Growth Factor (hß-NGF) and Neurotrophin-3 (h-NT-3) have been shown to 
control diverse aspects of neuron development by interacting with Trk-A. However, a fundamental 
question is how the two different neurotrophins, h-NT-3 and hß-NGF, signal through the common 
Trk-A to coordinate distinct stages of sympathetic neuron development [9]. Previous research has 
shown that h-NT-3 signals through cell-surface Trk-A receptors to promote axon growth. In 
contrast, hß-NGF supports both axonal growth and neuronal survival through internalization and 
trafficking of hß-NGF: Trk-A-containing signaling endosomes back to the cell bodies to regulate 
changes in gene expression.  
Ligand functional selectivity or ligand biased signaling is defined as the ability of 
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different ligands to activate distinct signaling pathways through a common receptor. It has been 
described for other ligand-RTK pairs [10][11]. Thus, this work will seek to decipher how Trk-A 
receptor-mediated specificity is achieved in response to two ligands. In chapter 4, we have 
shown that Trk-B interacts with three different ligands to generate diverse biological responses. 
In the case of Trk-B activation in response to Brain Derived Neurotrophic Factor (h-BDNF), 
Neurotrophin-3 (h-NT-3), and Neurotrophin-4 (h-NT-4), each neurotrophin induces a change in 
the conformation of transmembrane region of the Trk-B receptor, resulting in distinct kinase 
conformations. We have also found that the three ligands stabilize the TrkB dimers to different 
extents.   
In this chapter we test our hypothesis that the distinct biological responses of Trk-A to its 
ligands correlate with different stabilities and/or different conformation of the Trk-A dimers 
elicited by each ligand. This study will allow us to determine whether Trk-A and B receptors, 
which are highly homologous in terms of their percent sequence identities, recognize different 
ligands using similar mechanism. This hypothesis will be tested by using the FRET-based 
method which yields both thermodynamic and structural information about RTK dimers as 













In chapter 3 we have measured the dimerization of Trk-A in the plasma membrane. To 
allow for FRET detection, the receptors were tagged with fluorescent proteins (either mTurquoise 
(mTurq) or YFP, a FRET pair) at their C-termini, attached via a (GGS)5 flexible linkers. The cells 
were imaged with a spectrally resolved two-photon microscope and analyzed with a software 
package developed in the lab  to obtain (i) the donor concentrations, (ii) the acceptor 
concentrations, and, (iii) the FRET efficiencies, in live cells. A model describing the monomer-
dimer equilibrium was used to fit the data, yielding dimerization curves and dissociation constants 
that describe the stabilities of the dimers.   
Dimerization curves were first acquired for Trk-A in the absence of ligand as shown in 
chapter 3 in figure 3-1, yielding a two-dimensional dimer dissociation constant of 132 ± 37 
receptors/m2. Then, experiments were performed with Trk-A in the presence of saturating ligand 
concentration (380 nM) of h-NT-3 and hß-NGF. Data are shown in figures 5-1-A and 5-1-C, 
respectively. This concentration greatly exceeds the dissociation constant for h-NT-3-Trk-A and 
hß-NGF binding (1 nM), and ensures that all Trk-A dimers are bound to h-NT-3 and hß-NGF. The 
solid line in black in figure 5-1-A and 5-1-C represents “proximity” FRET and it is accounted for 
in figure 5-1-E to obtain FRET that occurs due to specific interaction between Trk-A receptor in 
the presence of ligands. Figure 5-1-E shows the corrected FRET as a function of total receptor 
concentration. We see that the corrected FRET is not concentration dependent, suggesting that 
Trk-A is dimeric over a broad range of concentrations in our experiment when treated with these 






Figure 5- 1: Comparison of the FRET data for full length Trk-A in the presence of saturating 
concentrations of h-NT-3 and hß-NGF. A and C: the FRET data plotted as a function of acceptor 
concentration for Trk-A in the presence of h-NT-3 and hß-NGF. Black straight line in the graph 
represents the “proximity” FRET. B and D: donor concentration and acceptor concentration for 
full length Trk-A in the presence of the two ligands. E, corrected FRET plotted as a function of 
total receptor concentration. F: histograms and Gaussian fits of FRET data for h-NT-3 and hß-
NGF. G, fraction of dimers as a function of total receptor concentration for Trk-A in the presence 



















Table 5- 1: Dimerization parameters for full length Trk-A in the presence of h-NT-3 and hß-

































The dimer stability of the h-NT-3 and hß-NGF-bound full length Trk-A dimers is very high, such 
that only 100% dimers are present at all Trk-A concentrations in the experiments as shown in 
figure 5-1-G. These results suggest that Trk-A forms stable dimers in the presence of both ligands. 
The Trk-A two-dimensional dissociation constant is therefore < 5 receptors/µm2 in the presence of 
these ligands, the experimental cut-off. To obtain information regarding Intrinsic FRET, we used 
equation 11 (since the dimeric fraction is 1). The data is plotted as histograms and was fitted with 
Gaussian functions to determine the mean and standard errors, shown in Table 5-1. The means 
give information regarding the average positioning of the fluorophores attached to the Trk-A 
receptor. There are no significant differences between the  Intrinsic FRET values reported in Table 
5-1, indicating that the two ligands stabilize similar conformations of the Trk-A dimer that are 
indistinguishable in our experiments.  
The FRET data for ECTM-Trk-A, with a kinase domain that has been removed as described 
in Chapter 2, in the presence of h-NT-3 and hß-NGF is shown in Figure 5-2. ECTM-Trk-A was 
treated with saturating concentration of ligands (380nM). Figures 5-2-A and C show FRET as a 
function of acceptor concentration in the presence of h-NT-3 and hß-NGF, respectively. The solid 
black line in these plots represents the contribution due to proximity FRET. Figures 5-2-B and 5-
2-D show the donor concentration versus the acceptor concentration for Trk-A in the presence of 
h-NT-3 and hß-NGF. The corrected FRET efficiency, which is due to specific interaction between 
ECTM-Trk-A receptors, is plotted as a function of total receptor concentration. As we can see, in 
figure 5-2-E, the specific FRET increases as a function of the concentration of the receptor. This 
indicates that the concentration of dimer increases, according to the law of mass action. A 
monomer-dimer equilibrium model was fitted to the corrected FRET data as shown in figure 5-2-
F. This fit yields two parameters: the dissociation constant, K, which reports on the strength of 
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ECTM-Trk-A interaction, and the Intrinsic FRET, a structural parameter. These values are 
reported in Table 5-2. Experimental binned fractions of dimers as a function of total receptors in 









Figure 5- 2: ECTM-Trk-A FRET data in the presence of h-NT-3 and hß-NGF is being compared. 
A and C: FRET as a function of acceptor concentration for h-NT-3 and hß-NGF.  The black solid 
line indicates the “proximity” FRET. B and D: ECTM-Trk-A donor vs. acceptor plot for the two 
ligands. E: corrected FRET as a function of total receptor concentration. F:  the dimerization 
curves for ECTM-TRK-A in the presence of hß-NGF and h-NT-3. The measured dimeric 
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fractions are binned and are shown with symbols, along with the standard errors. The solid line is 




























Table 5- 2: Dimerization parameters for ECTM-Trk-A in the presence of h-NT-3 and hß-NGF 



































As shown in figure 5-2-F, Trk-A dimer stability in the presence of h-NT-3 is much lower, 
when compared to the hß-NGF case. The two-dimensional dissociation constant for h-NT3 is 
456±75 rec/m2 and for hß-NGF is 25 ± 5 rec/m2 (Table 5-2). Yet, virtually all Trk-A receptors 
in these experiments are ligand-bound at this very high ligand concentration. This shows that Trk-
A in the presence of the two different ligands exhibits statistically significant differences in dimer 
stability in the plasma membrane. Unlike in the case of Trk-B described in chapter 4, we were not 
able to detect a difference in Intrinsic FRET, and therefore in the conformation of Trk-A dimer, in 












Figure 5- 3: A cartoon of Trk-A in the presence of h-NT-3 and hß-NGF, depicting no measurable 
differences in the fluorescent protein positioning when the two ligands are bound to the EC 
domain.  Instead we see differences in dimer stability for the Trk-A receptor for the two ligands 























As shown in figure 5-3 and table 5-2, the only change was observed in the stability of the dimer, 
specific to each ligand.  
5-3: Discussion 
  How multiple neurotrophins can interact with the same receptor to generate distinct 
biological response in neuronal cells is still largely unknown. Here we investigated how 
information is transmitted via the Trk-A receptor when two different neurotrophins interact with 
the receptor at the plasma membrane to produce different biological responses. We have 
previously shown in chapter 4 that Trk-B interacts with three different ligands, and each ligand is 
responsible for causing different conformational change and having different effects on the 
stability of Trk-B dimer.  
  We did similar experiments to investigate how two different ligands, h-NT-3 and hß-NGF, 
can interact with Trk-A in the plasma membrane. To determine the stability effects of h-NT-3 
and hß-NGF bound ligand, we measured and compared the thermodynamic stability of the Trk-A 
dimer in the presence of saturating concentrations of these ligands. We also measured and 
compared the Intrinsic FRET for Trk-A in the presence of saturating concentrations of h-NT-3 
and hß-NGF to determine any conformation differences in the Trk-A dimer.  
  As mentioned in the introduction section, hß-NGF, but not h-NT-3, results in endocytosis 
and retrograde trafficking of Trk-A receptors from axon terminals back to neuronal cell bodies to 
activate transcriptional programs necessary for sympathetic neuron survival. Conversely, local h-
NT-3-TrkA signaling in axons is sufficient to promote axon growth. This intriguing difference 
between the actions of h-NT-3 and hß-NGF observed in the biology of neuronal cells is due to 
the ligand biased signaling which gets initiated at the plasma membrane level. We have shown 
that h-NT-3-induced Trk-A dimers are less stable compared to hß-NGF-induced receptor dimers 
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(Figure 5-2, Table 5-2). However, we were not able to detect differences in the conformation of 
Trk-A dimer in the presence of the for two ligands (Figure 5-3, Table 5-1 and 5-2). Differences 
may exist, but they may be too subtle to be captured with the FRET assay.  
Together, this analysis suggests that Trk-A dimer stability correlates with distinct 
biological outcomes, i.e. stable dimers promote neuron survival and growth and weaker dimers 
promote axon growth, but not neuron survival. This new knowledge will enhance our 
understanding of the development of the nervous system, and will open the door for novel ways to 
control neuronal growth. We can engineer ligands that may stabilize the Trk-A dimer to a different 
extent, and these may induce new types of neuronal responses, which significantly differ from the 
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Chapter 6: Conclusions 
Despite decades of Receptor Tyrosine Kinase (RTK) research, the mechanism of RTK 
activation in response to their ligands is still under debate. Receptor tyrosine kinases (RTKs) are 
cell surface receptors, which control cell growth and differentiation, and play important roles in 
tumorigenesis. The main goal of my research was to study the interactions that control the 
activation of the Tropomyosin receptor kinase (Trk) family of RTKs in the plasma membrane, 
using a FRET-based methodology. The Trk receptors are expressed in neuronal tissues, and they 
guide the development of the central and peripheral nervous systems during development.  We 
quantified the dimerization of human Trk-A, Trk-B, and Trk-C in the absence and presence of 
their cognate ligands: human ß-nerve growth factor (hß-NGF), human brain-derived 
neurotrophic factor (h-BDNF), and human neurotrophin-3 (h-NT-3), respectively. We have also 
assessed conformational changes in the Trk dimers upon ligand binding. A crosslinking assay 
was performed for Trk-A in the absence and presence of hß-NGF to determine its oligomer state. 
We also investigated how one receptor can respond to multiple ligands to generate ligand biased 
signaling for Trk-B and Trk-C.  
In chapter 3, we have shown that our data support a model of Trk activation in which (1) 
Trks have a propensity to interact laterally and to form dimers even in the absence of ligand, (2) 
different Trk unliganded dimers have different stabilities, (3) ligand binding leads to Trk dimer 
stabilization and (4) ligand binding induces structural changes in the Trk dimers which propagate 
to their transmembrane and intracellular domains. This model, which we call the “transition model 
of RTK activation,” may hold true for many other RTKs.  
In chapter 4 and 5, ligand biased signaling was studied for Trk-A and Trk-B in the presence 
of additional ligands. Trk-B is known to interact with three different neurotrophins: Human Brain-
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Derived Neurotrophic Factor (h-BDNF), human Neurotrophin-4 (h-NT-4) and human 
Neurotrophin-3 (h-NT-3). All three neurotrophins are involved in survival and proliferation of 
neuronal cells, but each one initiates different downstream biological response. Our results show 
that the Trk-B dimers, when bound to the different ligands, have different dimer stabilities and 
different conformations. Trk-A function is differentially controlled by hß-NGF and h-NT-3. For 
Trk-A, we observed differences in the stabilities of the Trk-A dimers that are bound to hß-NGF or 
h-NT-3, but we could not identify differences in dimer conformations using the FRET assay. The 
differences in stability or conformation of the different-ligand bound Trk dimers may be 
responsible for ligand biased signaling and for generating different biological responses. This new 
knowledge about Trk activation and ligand functional selectivity can be used to design new Trk 
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